Skip to content

Author

K. Iwasaki

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Aug 2026

Atezolizumab vs durvalumab for extensive-stage small cell lung cancer in Japan: a real-world comparative analysis of costs and clinical outcomes.

Atezolizumab was associated with lower medical costs and similar survival outcomes compared with durvalumab in ES-SCLC, suggesting its use as a clinically comparable option with lower associated costs in Japanese real-world practice.

K. Hirano, Akito Hata, Y. Yamanaka et al. · 0 citations
Open access Aug 2026

Treatment patterns of patients with neuromyelitis optica spectrum disorder switched to inebilizumab in Japan: a claims-based retrospective study

In Japan, several biological agents with distinct mechanisms of action are available for the prevention of relapse in neuromyelitis optica spectrum disorder (NMOSD), including the B cell-depleting agent inebilizumab. Understanding the management of transitions between these agents is crucial for exploring safe sw...

Kenzo Sakurai, Maki Gouda, Toshimichi Mizuno et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.